Phase 2 study of TLK286 [canfosfamide; TELCYTA; Telik] in platinum resistant advanced epithelial ovarian cancer.

Trial Profile

Phase 2 study of TLK286 [canfosfamide; TELCYTA; Telik] in platinum resistant advanced epithelial ovarian cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2011

At a glance

  • Drugs Canfosfamide (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jul 2011 Actual end date (Jul 2005) added as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Actual initiation date (Jun 2001) added as reported by ClinicalTrials.gov.
    • 14 Jan 2008 Status change from in progress to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top